Language selection

Search

Patent 1193602 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent: (11) CA 1193602
(21) Application Number: 1193602
(54) English Title: PYRID-2-ONE DERIVATIVES, A PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM
(54) French Title: DERIVES DE PYRID-2-ONE; METHODE DE PREPARATION ET PREPARATIONS PHARMACEUTIQUES QUI EN RENFERMENT
Status: Term Expired - Post Grant
Bibliographic Data
(51) International Patent Classification (IPC):
  • C07D 213/64 (2006.01)
  • C07D 409/04 (2006.01)
(72) Inventors :
  • MULLER, WERNER H. (Germany)
  • BLUME, ERNST (Germany)
  • SCHLEYERBACH, RUDOLF (Germany)
(73) Owners :
  • HOECHST AKTIENGESELLSCHAFT
(71) Applicants :
  • HOECHST AKTIENGESELLSCHAFT (Germany)
(74) Agent: SMART & BIGGAR LP
(74) Associate agent:
(45) Issued: 1985-09-17
(22) Filed Date: 1983-03-25
Availability of licence: Yes
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data:
Application No. Country/Territory Date
P 32 11 395.1 (Germany) 1982-03-27

Abstracts

English Abstract


Abstract of the disclosure:
New pyrid-2-one derivatives of the formula I
< IMG > (I)
stereoimers thereof and salt thereof with a physiologic-
ally acceptable acid or base, and a process for the prepar-
ation thereof are described. The new compounds have an
antiinflammatory action and can be used as antiphlogistic
agents for treating rheumatic diseases.


Claims

Note: Claims are shown in the official language in which they were submitted.


-38-
THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A process for the preparation of a pyrid-2-one
derivative of the formula I
< IMG > I
stereoisomers thereof and salts thereof with
physiologically acceptable acids or bases,
wherein
R1 denotes hydrogen or alkyl having 1 to 6 carbon atoms,
R2 denotes a -CH=O, -COOR4 or -CH2-O-R5 group,
R4 represents hydrogen, alkyl having 1 to 12 carbon atoms
or benzyl, and
R5 represents hydrogen, alkyl having 1 to 4 carbon atoms,
alkanoyl having 1 to 9 carbon atoms, cycloalkanoyl having
4 to 7 carbon atoms, alkoxycarbonyl having 2 to 5 carbon
atoms, phenoxycarbonyl or a benzoyl group which can carry
one or two halogen, trifluoromethyl or alkyl or alkoxy
substituents, each of which has 1 to 4 carbon atoms, and
R3 represents 2-thienyl, 3-thienyl, tert.-butyl or a
phenyl group which can carry one or two substituents
denoting halogen, trifluoromethyl or alkyl or alkoxy,
each of which has 1 to 4 carbon atoms,

-39-
in which a compound of the formula II
< IMG > II
wherein R3 is as defined above is reacted with a compound
of the formula III
(IMAGE) III
wherein R1 and R2 are as defined above and X represents
halogen, alkylsulfonyloxy, substituted or unsubstituted
arylsulfonyloxy or the radical of a reactive ester.
2. A process as claimed in claim 1 in which the
compound of the formula II is prepared by a process in
which a compound of the formula IV
IV
< IMG >
is reacted with an acrylic acid ester of the formula V
< IMG > V

-40-
to give a compound of the formula VI
< IMG > VI
this compound is then cyclized by means of ammonia to
give a compound of the formula VII
< IMG > VII
and the latter is finally dehydrogenated to give a
compound of the formula II, R3 in the above formula
having the meaning mentioned in claim 1 and R6 being an
alkyl radical having 1 to 6 carbon atoms.
3. A compound of the formula I as defined in claim
1, whenever obtained according to a process as claimed in
claim 1 or claim 2 or by an obvious chemical equivalent
thereof.
4. A process as claimed in claim 1 wherein a
compound of the formula I in which R2 is -CH=O or a
-CH2-O-R5 group is prepared by reducing a compound of the
formula I in which R2 is a -COOR4 group, to give the
-CH2OH group, then oxidizing this group to give the -CH=O
group or reacting this group with an alkylating or
acylating agent to give the -CH2-O-R5 group.

-41-
5. A pyrid-2-one derivative of the formula I as
set forth in claim 1 wherein R1, R3, R4, and R5 are as
defined in claim 1 and R2 is as defined in claim 4,
whenever obtained according to a process as claimed in
claim 4 or by an obvious chemical equivalent thereof.

The OCR engine was not
able to convert this image.

Description

Note: Descriptions are shown in the official language in which they were submitted.


~36~
The invelltion r~lates to pyri~-2-one derivatives, a
process for their manufacture, and pharmaceutical preparations
~hich con-tai~ Pyridone derivatives aild have an antiinfldrnm~o~y
action.
Kno~1n antiinfla~natory agents especially those f~r
treatin~ rheumatic diseases suEfer from the dis-
advantage o-f consid~rable side effects which rnanifest tilem-
selves, in a troublesome manner, in part;cular in the case of
prolonged treatrnent. There ;s, therefore, a need for com-
pounds having an ant1phlo~istic action which exhibit improved
gastric acceptab;l;ty.
The invention relates to pyr;d 2-one der;vatives of
the formula I,
R ~ R1 (I)
stereo;somers thereo-F and salts thereof with a phys;ologically
acceptable acid or~ ;f R2 represents a carboxyl group~ with
a base, ;n wllich formula
~ denotes hydrogen or alkyl having 1 to 6 carbon
atoms,
R2 denotes a ~CH-0, -COOR~ or ~C1l2~0-R5 group,
R4 representing hydrogen~ alkyl havin~ 1 to 12 carhon
atoms or ben~yl and
R5 representin0 h)~drogen~ alkyl having 1 to 4 carbon
atoms, alkanoyl ha~ g 1 to 9 carbon atoms, cyclo~
alkanoyl ha~.~ing 4 to 7 carbon 3~0ms~ alkoxycarbonyl
~,.

~3~
havintJ 2 to 5 carbon atomsr phenoxycarbonyl or a
benzoyl ~roup which can carry one or two halogcl1,
trifluoromethyl or all;yl or alkoxy substituents,
each of which has 1 to 4 carbon atoms, and
R3 represents 2-th;enyl~ 3-thienyl, tertO-butyl or a
phenyl group which can carry one or two substituents
denot;l1g halogen, trifluoromethyl or al~yl or alko~y,
each of which has 1 ~o b, carbon atoms.
Pre-Ferred compounds of the formula I are those in
which R1 represents methyi, ethyl or propyl and R2 denotes
a -Cl-l=O, -COOCH3, ~COOC2H5~ ~COOH or -Cl~2~0-R5 group. In
this connection R5 denotes hydroyen, a formyl, acetyl~ pro-
panoyl, n-butanoyl, 2~2-d;methylpropanoyl, n-octanoyl, cyclo-
propanoylr cyclobutanoyl, cyclopentanoyl or cyclohexanoyl
group, or a rnethoxycarbonyl, ethoxycarbonyl or benzoyl group~
the latter bein~ either unsubstituted or being monosubsti-
tuted by fluorine, chLorine, bromine, trifluoromethyl or
methyl.
In addition to the 2-th;enyl, 3-thienyl and tert.-
butyl groups, a suitable group for R3 ;s, in particular, thephenyl group which is either unsubst;tuted or carries one
subst;tuent, fluorine, chlorine, brornine, trifluoromethyl',
methyl and metho~y being preferred substituents~
Compounds of the formula I which should be singled
out particularly are those in which R1 represents methyl or
ethyl, in which R2 is ~CH=O, -COOCH3, ~COOC~Hs~ ~COOH or a
-CH2-o-R5 ~roupr R5 denot;n~ hydrogen, acetyl, propanoyl, 2
rr,ethylpropanGyl or n-butanoyl, and ;n which R3 is 2~thienyl~
phenyl~ ~-fluorophenyl or tert~-butyl.

~3~
. ~,
Compouncs of the formula I which are very particularly
preferred are those in which R1 represents methyl and R2
represents a ~COOC~13, ~COOH or CH-~0~ yroup and R3 denotes
2~tl1ienyl~ above all phenyl or ~ fluorophenyl.
The compounds o~F the general ~formula (I) also display
their essentia! propert;es in the form of the;r salts. Any
physiologically acceptable acids are su;table -For the pre-
paration o-f acîd addition salts~ These ac;ds ;ncludeO pre-
ferentially~ the hydro~en hal;de ac;ds, such as, -for example,
hydrochlor;c and hydrobromic acids, and also nitric acid
and also phosphoric acid or sulfuric ac;d~ Preferred orgai1ic
ac;ds are monoFunctional and biFunctional carboxylic ac;ds
and hya'roxycarboxyl;c ac;ds~ such as, for example, acetic
acia, maleic acid, oxalic acid, succinic acid~ fumaric acid,
tartar;c acid, ci.ric aci~, sal;cylic ac;d, sorbic ac;d,
lact;c ac;d and sulfonic acids, such as, for examplef p-
toluenesulfon;c ac;d, methylsul-Fonic ac;d, phenylsulfon;c
acid and 1,5 naphthalenedisulfon;c ac;d~ The salts of the
compounds of the formula (I~ can be obta;ned ;n a simple
manner by custornary methods of salt formation, for example
by dissolvin~ a compound o-f the formula I ;n a su;table ;nert
solvent and addin~ the acid, for example hydrochloric acid
or n;tr;c acid, and can be ;solated in a kno~n manner, for
exampie by filtration, and can, if appropriate~ be purified
2S by washing with~ or recrystall;zat;on frorn~ an inert or~anic
solvent.
The salts of the compounds oF the formula I with
physiolog;calLy acceptable bases are advantageously sod;urn~
potassium~ magnesium or calcium salts of those compounds

~3~
of the follnula I in which R2 denotes a carboxyl group~
The ;nvention also relates to a process -for the pre-
paration of the compounds of- the formula I, which comprises
reacting a compound o-f the formula II
~0
R3 (II)
with a compound of the formula III
X -- ~ ~ R2 (III)
h;ch forrnulae R1, R2 and R3 have the mean;ngs indicated
above and X represents haLogen, alkylsulfonyloxy, substituted
- 10 or unsubstituted phenylsulfonyloxy or the radical of a re~
active ester~ In particular, X denotes here chlorine, bro-
mine, methylsulfonyloxy, phenylsulfonyloxyr 4-metl1ylphenyl-^
sulfonyloxy or 4~chlorophenylsulfonyloxy or the radical of
a react;ve ester, such as trifluoroacetoxyr phenylcarbonyl-
oxy or methoxycarbonyloxy.
The process accordir.g to the inven~iorl is carriedout between 30 and 150C, preferably between 40 and 1Z0C,
in the presence of a base, in water or in an inert organic
solvent, such as N~N dimetl1ylformamide, N,N-dimethyl
acetamide~ d;rnetl1yl sulfoxide, aceton;trile~ N methyl
~--pyrrolidolle~ dioxaner tei:~al~ drorlJranf, ettlel~ /t Ill~?thyl~-2~

336~
pentanone, methanol, ethanol, isopropyl alcohol, propanol~
butanol~ pentanol, tert. butyl alcohol, methylglycol, d1-
methylglycol, dimethyld;~lycol, methylbutyldt~lycol or poly~
ethylene glycols. In add;lion, it is also possible ~o use
methylene chlor;de or an arornatic hydrocarbon~ such as benz-
ene~ chlorobenzene, toluene or xylene and also mlxtures of
t-he solvents mentioned aboveO
Examples of suitable bases are alkali metal or
alkal;ne earth metal carbonates, bicarbonates, hydroxides~
alcoholates or hydrides, such as sodium carbonate, sodium
b;carbonate, potass;um carbonate, sod;um hydrox;de, sodium
methylate or sodium hydride~ It ;s also poss1ble to employ
organic bases here, such as tr;ethylam;ne~ tr;butylamine,
ethylmornholine pyridine~ dimethylalninopyridine or quinoline~
The reaction also takes place with good yields under
conditions of a phase transfer reaction, by allo~ing the
reactants to react with one another in one o~ the above sol-
vents~ w;th vigorous stirring~ in the presence of a phase
transfer catalyst and either a powdered alkal; metal hydrox-
ide or a concentrated aqueous solution of an alkali metal
hydrox;de, and within a temperature range between 20 and
150C.
Examples of sui~able phase transfer catalysts are
tr;alkylbenzyiammon;uln or tetraalkylammonium halides~
hydroxides or bisul-fates, preferahly having up to 1? carbon
atoms ;n the alkyl radical, or crown etl1ers~ such as 12 crown~
4, 15-crown-5, 18 crown-6 or diben~o-18~crowl1-6~
h compound of the formula I in whicl1 F~2 is a -Cl~2 o-R5
~roup is advantageously prepared by reducing a compound o-f

36~
-- 7 ~
the formula T ;n which p~2 is a CoOR4 yroup, to give ~he ~CI-l20
group, which ;s then reacted with alkylating or acylating
agents to g;ve the CH~-O-RS group. Examples of sui.able
reduc;ng agents are lithium alum;num l1ydrider diisobutyl-
aluminum hydride or sodiurn borohydride, whicli are employeclin an inert solvent at temperatures between O and ~0C~
The alkylation and acylation reactions are carried
out in an inert solvent in the presence of a suil-able base
and at temperatures between 10 and 1~0C.
The preparation of compounds of the form-lla I in
which R2 is a CH-O group is advantageously effected by
oxidizing cornpounds of the formula I in wl1ich R2 is a ~CH20H
group. Oxidizing agents which are suitable for this purpose
are lead tetraacetate, chromium trioxide~ cl1rolnium~6 oxide
bis-pyridine complex, manganese dioxide~ Ni203.3H20, dimethyl
sulfoxide/tr;fluoroacetic anhydrider dimethyl sulfoxide/
oxalyl chloride, dirnethyl sulfoxide/cyclohexylcarbodiimide/
phosphoric ac;d, the pyridine/S03 complex or aluminum iso-
propoxide in combination with a carbonyl compound, such as
4-methoxybenzaldehyde, 2-chlorobenzaldellyde, cinnamaldehyde
or benzophenone. In addition to the solvents rnentioned abo~e
for the reaction of the compound II w;th the compound IXI,
glacial acetic acidr chloroform~ carbon tetrachloride and
petroleum ether are also additionally used~ llowever, a
cataly~ic oxidation with the aid of a catalyst containin~
a noble metal of the VIIIti- group, in particular platinum
and/or palladiunlr is also possiblen
The compounds of the formula II ~hich are reqlJired
. --
as intermediate products can be prepared ei~her in accordance

3~
~ith the process described by J. Thes;ng et al., Chem. Ber.
90, 7il (1957) or analo~ously to the instruct;ons giver, by
F~ ~rohnke et al. in Chem. Ber. 103, 322 et sec1,. (1970).
However, it is particularly acivanta~eous to react a compound
of the formula IV
R3 - C - Cl-13 (IV)
o
with an acrylic acid ester o-f the formula V
CHz - C~l - C - oR6 (V~
g
to give a compound of the formula V
R3 - C - CH2 - Ci~2 - CH~ ~ C - oR6 (VI
g 11
wh;c1~ I,en cycli~ed by medns o~ arnmon;a to cj;ve a cori7pour,d
of the formula VII
~ '
R3 1 (VII~
~ [
wh;ch is finally dehydrogenated to g;ve a compound of the
15 formula II. In the formulae ment;oned above, R3 has the
mean;ngs ment;oned in cla;m 1 and R6 is an alkyl rad;cal
having 1 to 6 carbon atolns.
The preparat;on of the compound VI froln the ketone
IV and th~ acryl;c acid ester V is carriecl out at ternpera
tures bet~Jeen 20 and 220C~ under alkaline cond;t;ons ;n
an inert solvent~ It is also possible to dispense w1th the
use oi solvents in this reaction and to carry out the reaction
~lithout a diluent. The base whicl1 is added to the react;on

~L~9~
_ 9 ~
mixture is preferably a pr;Mary amine, such as methylam;ne,
ethylamine~ propylam;ne~ isopropylamine, butylam1ne, cyclo-
hexylaln;ne or the ~ -N~alkylam;noprop;onate wl1;ch ;s formed
~rom the acryl;e ester and arn;ne usedO The rract;on 1s
5 earr;ed out ;n the presence of eatalyt;e amounts oF al1 aeid,
sueh as benzo;c ac;d, phenylsulfon;c ac;d~ toluenesulfonie
ae;d, salieylie ac;d~ acet;c ac;d or acryl;c ac;d~
The compound VI is then reac~ed with ammon1a in an
inert solvent or w;thout a d;luent a1: a temperature between
10 100 and 250C, preFerably in an autoclave, to g;ve the
eompound VII. The latter ;s then dehydrc)~enated usincJ a
dehydrogena~;on eatalyst, such as pallad;um-on-charcoal~
to give the compound II.
The cenpoundc of the for!nula III which are used as
1S starting materials are known.
It can be seen from the formula I that the colnpounds
aeeord;ng to the invention eonta1r at least one eenter of
asymmetry in the ~-position in relat;on to the o~y~en atom,
prov;ded that R1 does not denote hydrogen. The racema~es
of the Formula I which can be obtained if raeemic eompounds
of the formula III are used, can be resolved into the;r
optieal ant;podes in a eustomary manner. Th~s compounds
of the formula I in wh;ch R2 denotes COOH ean be trea~ed
us;ng an optically active base. The optieal antipodes of
2~ compounds of the formula I are obtained in an advantageous
manner if the startil1g mater;als of the formula IJX are
already optically active.
~ y v;rtue of the phar!nacological tests wh;ch follow
and the results obtait1ed tr,ere;n, the eompounds accordi~

1~33~
~ 10 -
to the ;nvention can be c!esignated suhstances which have
a pronounced ant;inflamnlatory action and, at the same time,
a low toxicity. They can~ therefore, be used as drugs having
an antiphlogistic action, in particular against rheumatic
diseases.
1~ Adju\~ant arthritis
_._ ___
The tests were carried out by Pearson's method
(Arthr;t. Rheum~ 2~ 440 (1~5~ The test animaLs used
were male rats of a l~is~ar Lewis strain having a body weight
betueen l30 and 200 9. The compounds to be compared were
administered orally every day from the 1st to the 5th day
of the test~ The anirnals in a control group only received
the solvent. Groups of 8 an;mals were used for each dosage
and in the ~ontrol groupn The criterion of action used was
the reductioll in the increase of pau volume compared w;th
that of the untreated control ~roup~ The ED50 values were
determined graphically from the dose activity curve.
2. Ga ~ on
The tests were carried out on groups of 10 male
Sprague-Dawley rats having a body weight of 200~300 9. The
feed was taken away, while free access to dr;nkin~ water
was permitted, from 48 hours before the aclministration of
the compounds to be compared until the animals were sacri-
ficed~ The rats were sacrificed 24 hours after the oral
adm;nistration~ and the stomachs were taken out, cleaned
under runiling water and ;nspected for lesions to tl-le illUCOUS
membranes~ r~ll les-iorls visible to the naked eye were coun~ed
as ulcers. Ttle propoltion of ar,imals havin~ ulcers a. each
dose ar~d the ub50 as specified by lichtfield and ~J;lcoxon

36~
(J. Ph~3rmacol. exp~ Ther. 96, 99 (1949)) were determ;ned~
3 . Acute t_x1 c~ty
Acute toxici1y W2S deterrl7ined by standard methods
using rats of the Sprac7lle-Dawley strain~ 6 anirnals were
5 used per dosaye. The LDSo values were determined by the
method of LichtF;eld and ~Jilcoxon~
CEI3
CEi - R2
2 ED50 50 50 50
Substance R Adj~Nant arthritis Gastric ulcers 7r~iex
__ _ ~ . ~ _ _
Sulindac 13.0 rng/kg 26.0 mg/kg 2
_ _ _ _~ . ... ._
Naproxen 15.0 mg/kg 21~0 mg/kg 2
~ . _ _ _~ .
Exar,ple 4 COOH 20.0 n~7/kg 175 nlg/kg 9
~ __ .. .. _
Exarrple 7 CC~C2H5 15.0 mg/kg 125 rr~/kg 8
~ ............... _ _ _. . . I
Exarriple 9 CHzOH 20.0 n~g/kg 220.0 rrg/kg 11
_ ._ ~
S~bstance50 TI D50/ED50)
Acute toxicity in~7ex
___ . ~_~
Naproxen 3~5 n~7/kg 26
__ _____ _ _
Exarn~)le 9 1,C00 rr~7/kg 50

~3f~
- 12 ~
The connpounds tested exhibited a clear advant&ge com-
pared w;th the known comparison folmulations sulindac and
naproxen on the basis of their excellent gastric tolerance
by rats, which constitute a model animal of good effeccive~
ness as an indicator of the most imporcant s;de effect of
this class of substances in humans. A therapeutic index
which is at least 4 times that of the compar-ison formulations
is derived from these tests. In add;tion~ the alcohol
(Example 9) has an acute tox-icity tLD50 1J00~ mg~kg) which
;s unusually good For antiphlogistic agent~ and is more than
twice the LD50 of naproxen (395 rng/kg)~
The drugs accordirlg to the invent-ion can be admini~
stered orally, rectally or parenterally.
Examples cf su;table scLid or l;quid ph3rmareutical
forms for formulation are granules, powders, tablets, dragees,
(micro~capsules, suppositoriesr syrups, emuls;ons, suspen~
sions, drops or injectable solutions and also form-llations
having a protracted release of active compound, which are
customarily prepared by using auxiliaries, such as excipients,
disintegrators, binders, coating agents, swelling agents,
slip agents, lubricants, flavoring substances, sweeteners
or solubilizers~ Lactose~ mannitol and other sugars, talc~
lactalbumin, gelatine, starchr cellulose and derivatives
thereof, vegetâble oils, polyethylene glycols and solvents~
such as, for instance, ster;le water~ may be ment;oned as
examples of aux;liaries which are ~requently used~
The formulatiorls are preferably prepared and admilli
stered in dosage un;ts, each unit conta1n;ng a specific dose
o-f active substance accord;ng to formula I~ In the case

~19~
- 13 ~
of solid dosage un1ts, such as tablets, capsules or supposi-
tor;es~ th;s dose can be up to 1,000 m9, but preferably 50
to 300 mg~ and in the case of injection solutions in the
form of ampuls ;t can be up to 200 mg, bwt preferably 20
to 100 mg~
Depending on the effect;veness of the compounds
according to formula I on hulnans~ the daily doses indicated
for the treatment o-f an adult patient suffering from inflam-
~ atory processes are 100 to 500 my of act;ve compound, pre-
ferably 200 to 300 mg, in the case o-f oral admin;strat;on,
and 20 to 150 m9, preferably ~0 to ~0 mg~ in the case of
;ntravenous admin;stration. Undrr certa;n circurnstances,
however, it is also possible to administel higher or lower
da;ly doces. The daily ~Jose can be administered either by
a single administrat;on in the form of an individual dosage
unit or several small dosage un;tsr or by the repeated admii-~i-
stration of subdivided doses at speci-fic intervals~
- ~he ;nvention is illustrated by means of ~he follow-
ing examples.
Example 1a
_
Methyl Dl-2-(6 phel1ylpyridirl-2~oxy) propanoate
34.2 g of 6-phenylpyrid-2-one are dissolved in 200 ml
of dimethylfrJrmamide~ 24~5 g of methyl Dl- ~-chloropro~ionate
and 27.3 9 of K2C03 are added successively and the mixture is
then stirred for ~ hours at 90C~ The reaction mixture is
then filtered while hot and the f;lter cake is washed with
a little acetone. The acetone and the ~olvent are removed
by distillation under redured pressure (dowl1 to 13 mbar),
and the residue is distillrd urlder a greatly redured pressure

1~3~
14 -
throuyh a 20 cm Viyreux column~ This g;ves 44.3 g (86% of
theory) of a colorless oil of bo;ling point 177C at 3 mhar.
Dimethyl sulfoxide, d;methylacetamide~ N-methyl~2-pyrrolidone
or ~irnethyldiglycol can also be used as the solvent, with
sodium carbonate as the base~ in the same procedure as des-
cribed above.
Example 1b
The following compounds of the formula I, listed
in Table 1, are prepared in accordance with Exa~ple 1a, but
us;n~ equ;valent quantities of the corresponding compounds
of the forrnulae II and III tDL-, D- or L~forrrl)~

.9;.3~
- 15 -
Ta~le 1:
~ O H ~ ~1
R H R
H
Comp~r~ X R3 R1 R2 . ... : ::
_ _ _ . . . _ . . . _ _
1.1 Cl CGH5 H ,~ M p.: 62C
_ _ . _ . . . _ 3 D,L
1.2 Br C6H5 CH3 -C-O-C2H5 B P 2 5 = 1 7 5-1 7 7 C
. .. ___ . D,I.
1.3 Br C6H5 CH3 O Mp.: 74C
-C-C-GH(c~3)2 D,L
__ _ _ . .... __ _ ___
1.4 Cl C6H5 G~3 ( 2)11 3 MP 39-LIOOC
~ ~ --~---- --- - - . - - ~---
1.5 C1 C6.Y5 CH3 -C-O-CH2-C6ll Mp 67-68 C
.. . _ . . . _ _ ,.. _
1.6 Br C6H5 C2H5 O
. .. _ ... _ . ___ . . ~
1~7 Br C6l~5 C2H5 -C-O-C2H5 Bp~ = 187C
. __ ~_ _ . .... ~
1.8 BrC6H5 ( 2)2~3 ~l
. -C-o-C~13
__ _~ ~ ..... _ __ ~ _. .. ~
1.9 Br C6~35 -~G~2)2~ 3 O BP~2 _ 185C
_ . ~ - ~C--O-C2~5 D,L
. . . _ _ _~_ _ _ _ ~._

~ 16 _
Tab l e 1 cont i n~led
___ _ _
Ccnpound X R3 R1 l R2
~ - _ _ . . . .. _ __
1 . 10 Br CG~5-CH (CE13 ) ~ ,~ . . . .
_ _ __ . _
1.11 -I2 C6H5 H C~2{> (C~ 2) 3 3
~3
_. __ _ , ~
1 . 12 _S02 t~6H5 H ~2~C 13 Bp O ~= 128-
a~3 _____ ~ _ ~ L,L
.1 3 B- C~ O C~i O ~ ~P 1 -
3 ~> -C~-C2H5 ~ 180~C
__ __ . __ __ ___
1.1 4 13r ~3{~ ~ c~3 -C-~C2.~15
~ _ _
1.15 Br CH3~ CH3 -C~C2H5 E~p 0 6 - 14~C
1 . 16 Br a~3 C~13 -'-~C2~15
__ ~ _ . ___ ._
1.17 Br (~ 3 ~{) CII
__AA_A_ .___ __ . _ _ . .. _ _
1.18 B~ ~ ~ U.~3 -C (}C2'H5 O 1 = 125-
___ ___ ,~

~336~
_ 17 _
Tab ~ ~ 1 cont i nued
_~____ _
C~I~b. d X R~ R 1 R2
_ __ _ ~
1 .19 3r F ~C-~ CE13 -C~C2~5 __~ __
1 . 20 Br Cl-(~ CT-I3 ~ (}C~5 Bpo 5 1 5 5 -1 6 0 C
__. _ __ _ __
1. 21 3r Cl C ~3 C C2~5 ~___~_ __
1. 22 Br ~ C l3 _~___ _
1. 23 Br Gi3 ~ O
¢~ C-~C~3
. S .
__ . __ _ __
1 . 24 Br 1 3 CH3 O
}~3C 1- -C-~C~15
CH3
_ ___ ~
1.25 Cl C,H~ Ct~ O Bp 0.8 150-154C
D ( + ) ~C~3 ~G] D = + 1 1 . 4
~G~C' 3)
~__ _ ___ -- _ ~ _ _ _ ._. .
1. 26 Cl ~ a~3 O
__ _ --C-'~I
1 . 27 Cl 1 3 aI3 O
1~3C-C- -C~3
~3 _ ~
.. .. __ _ _ ___ _.__... .. ____. , _ ___ ____._. .

_ 18 -
Tab l e 1 cont i nued
_~ ___
Comp~nd i ~ R3 . R1 R~
No. . ..... .. .. ..
1.23 ___ _ _____. ____.___ ___ . .... .
~1 -C-~-C1~3
1.2g Cl - - C~13 O_ _~
<~- ~-C~13
~3
___ ... _ _ _ __ __ .... __ _ ... _ ..... _ ._.___
1.30 Cl Cl~ G13 " Bp o 6 ~ 150-155C
D ( ~) C-OC~3 la] ~5 = * 11,4 ~C'Cl3)
_ ___~ __ ... ___ ... .. _
1.31 Cl H3C~ C~3 ~ Mp . ~102C
D(+) -C-{~3 ~]D = +1~.3 (CHC13)
.. . --_ . _ ~
1.32 Cl ~ C~ ~3 ~ Mp,: 125--l 26
D (~- ) -C-CX~I ~ ] D +14 - (CHC13 ~
1.33 C.l . __ . _ ___ ~ ___ _.______
D(+) F~ C~13 --C~ 3 Bpr 0 1 = 127-135 C
_ [a] 25 = + 11.2 (C~Cl3)
. _ _ __.___ . .
1.34 Cl F~ G O Bp - O ? - 145-150&
D~+) \_~r~ ~3 - C-CC21l5 [o]~5 = ~11,4 (CrlC
1.35 Cl . . G~ _ ~ ~~ 0 6 = 1so-l 52
L (-) ~._ 3 -C-OC2H5 [~] 25 -12,1 (c~c13)
1.36 Cl _~.. _ __ _____ _~_ ___.~_
--CI~O~-' C - ~ --C-CC2H5 Mp : 70 _
~_ ~ ._ _____ . __

.~936(~'~
~9
Example Z
____
Ethyl DL~2 C6~ dichlorophenyl)-pvrid;n~2~oxy~pro~arloate
24 g oF 6-(3,4~dichlorophenyl~-pyrid-2-one are added
in port;Gns, and while st;rr;ng and cooling, co a suspension
of 3 g of sodium hydride (an 80% strength d;spers;on ;n o;l)
;n 2DO ml of d;methylforrllaln;de at such a rate that the tem~
perature does not exceed 30Cr st;rr;ng ;s cont;nued at
40C unt;l ttle evolut;on of hydrogen is completer and 1~.1 9
of ethyl DL- ~ bromopropionate are then added dropwise and
stirr;ng ;s cont1nued For 5 hours at 80C~ After cooling,
the reaction mixture is poured into 500 rnl of ice water,
the mixture is extracted with methylene chloride, the
extract ;s worl~ed up in a customary manner and the residue
;s d;stitled under ~ greatly reduced pres~uren Th;s gives
25.5 g (75X of theory) of mat2rial of boil;ng point 1~0C at
n.3 mbar, melt;ng po;n~: 70C.
Example 3
_
DL~2-~6~phenylpyridin~2~oxy)~ethanoic ac;d
0.3 g of tetrabutylammon;um hrom;de is added to
a solution of 17u1 9 of 6-phenylpyrid-2-one in 1ûO ml cf
dirnethylformamide~ and 1~3 g of very finely powdered KOH
are added while stirr;ng vigorously~ 12~2 9 of ethyl chloro-
acetate are then added dropwi3e at 80C~ v;gorous stirring
is continued for a further 4 hours. 10 ml of water are addedr
stirr;ng îs continued for a further 30 m;nutes and the solvent
is removcd under reduceo pressure~ The residue ;s taken
up in 40 ml of waterr the solution is ac1di-Fied with 2 N H2S04
and the precipitated ac;cl ;5 filtered ofF wi-h suction~ dried
at 500C ;n a dryirlg cabinet and .hen recrystall;zed from

33~il)'~
~ 2~ _
di;sopropyl ether/hexane. This gives 1~ g, melting point
125~126C.
Example 4
. .
DL-2-~6-phenylpyridin-2 oxy)~propanoic acid
A mixture of 12.9 g of methyl DLw2-(6-phenylpyr;din-
2-ox,~?-propanoate, 2~4 g of NaOH and 10 ml of methanol is
heated at 80C for 30 minutes~ AFter cooling, the mixture
;s acidifed w;th 2 N H~SO~,~ and the precipitated acid is
dried at 50C in a drying cabinet and is then recrystalw
lized from di;sopropyl etlier/hexane. This gives 10.9 g (~0%
of theory) r melting point : 142-143C.
Example 5
Tlle following compounds of the formula I, listed
in Tab-~ 2~ al~e prepared i,l accordance W jth Example 4,. but
using corresponding quantities of compounds from Table 1
and NaOH.

~3~
- 21 -
Table 2
~1 0
~ ~0 - C - ~C - O - ~
Cornpour~ 1 R3 R1 Prepared -frcm M~p.: [ C] [a]D (CE~301i)
- . ~ Cc~lpound No _~--
2 . 1 C6H5 -C2H5 1 . 7 0
_._ .. _ . _ _
2.2 ~ CH3 1.22 154 oo
._ _ _ _
2 . 3 ~ CH3 1 . 21 ~ 0
. . _ . __,
.~ a- l 0O
2 . S H3C- IC- GH3 1 . 24 Oo
~ _
2 . 6 H C-~>-- CH3 1 .15 169 O
~ ~.. __. ~
_ ..
2. 7 F3C-~ Cli13 1 .19 0
_ ___ ~_~ ... .
D ( + ) Cl~>_ C 33 1 . 3 ~) 1 5 6 - 1 5 7 + 7 . 0
~ ___ ____

~93ti~
- 22 _
Tab l e 2 con t i nued
_
Ccnpound 3 ~1 Prepared fran M.p: [ C] k~D (C~.3n~)
No. Cony: ~uncl l\b.
__ .~ ._ ~_ ~ ._
D(+) ~I C-~ C~T3 1.31 169-170 ~ 7,2
. _ ~ . _ _ _
2 . 1 0 ~3C~ CH3 1 . 3 2 1 6 0 ~ 1 1 . 0
_ __ . _. ~ _ . ___ _ . _ _ _
2 . 1 1 ~ CE~3 1 . 33 13--1 19 t 9 . ~1
_ . __ _~___ ~._ . _ _ .
2 . 12 _ __ _ 3 1 . 3 5 1 25-1 2 6 -10, 0
_. ~_ ..

1~93~
- 23 -
Examp e_6
Dt~)-2~(6~- henyLpyridin 2-oxy)-propanoic acid
25.7 9 of methyl D(~-2~(6 phenylpyridin~2-oxy)-
propanoate, 20 ml of methanol, 20 g of l-l20 and 4.8 9 of NaOt1
are stirred at 75C for 3 hours and, after cooling~ are
acidified with 2 N H2S04. The precipi~ated ac;d is pressed
out on a clay plate and dissolved in diisopropyl ether, and
the solution is dried with Na~S04. A^Fter f-iltering~ hexane
;s added to the hot solution until cloudiness is formed. On
cooling, 18.5 9 (76% o-F theory) of product crystallize out,
melting point: 126C~ specific rotacion C ~25 - ~ 4
(CH30H).
Example 7
_
~ 2~(6-phcnylpyr,d-r;-2~oxy)-prop3noate
12aZ 9 of P(~-2-(6-phenylpyridin~2-oxy) propanoic
acid, in a mixture of 50 ml of toluene and 30 ml of ethanol,
are bo;led under reflux for 5 hours, the mixture of solvents
is removed by distillation and the residue is fractionated
under a greatly reduced pressure~ This yives 11~ 2%
o-f theory) of product, boiling point 138-142C at 0~5 mbar,
specific rotation ~320 = 1ODOO (CHCl3).
Example 8
6-Phenylpyridin-2--oxyethyl ethyl ether .
A suspension of 8.6 9 of 6-phenylpyrid~2-one. 0.5 9
of tetrabutylamrnonium bromide, 5.4 g oF Z-chlorodiethyl ether,
100 ml of toluene and 20 ml of 50% strength sod;um hydroxide
solution is vigorously stirred -For 5 hours at 100~. After
cooling, 30 ml of water are added~ the orgarlic phase 1s
separated of~, r;nsed ~Jith 2 N NaOH and dried over Na

36~
- 2~ -
the solvent ;s removed under reduced pressure and the residue
;s distilled under a greatly reduced pressure. This gives
7.9 9 t66% of theoryj of- a colorless oil.
Example 9
___
DL-2 ~6-phenylp~r~__n-2-oxy~ _ nol
A solution of 13.6 g of ethyl DL~2-(6-phenylpyrid;n
2-oxy)~propanoate in 30 ml of absolute diethyl ether is added
dropwise, at room tempelature and !Jhile st;rring, to a sus
pension of 2~05 g of L;thium alum;num hydride in 75 ml of
absolute d;ethyl ether, and the m;xture is st;rred under
re-flux for 1 hour. After cooling, the m;xture is hydrolyzed
w;th water and acidified l~ith 10% strength sulfur;c acid,
and the aqueous phase is saturated with NaCl and is separated
off, the remainder is extracted with ether, the combirled
organic phases are dried over Na2S0~ and the solvent is removed
under reduced pressure. 1he residue is distilled as described
in Example 1a. Th;s gives 10.9 g ~95% of theory) of product~
boiling point 181C at 6-7 mbar.
Example 10
D(~)-2 (6 ~ din-2 oxy _propano_l
11.0 g (96~ of theory) of product, boilin~ point
180C at 6 mbar, spec;fic rotation C~ ~20 ~ -~2.1 ~CHCl3),
are obtained ;n accordance with Example 9, but-using 1209 g
of metl1yl D(1-)~2 ~6~phenylpyr;din 2~oxy)-propanoate~
Example 11
-
The follo~ g compounds of the formula I, listed ;n
Table 3, are prepared ;n accordance w1th Example 9~ but us;ng
corresponding quantities or compounds from Tablc 1 and lithium
aluminum hydr;de:

i~L936~'~
-. 25 _
T a b l e 3
/~ C) - C - CH2 ~ C~E-I
R3 ~!
C~o~Jn,d I ~3 R Prepared frcrn
No~ i 1 Con~nd No.
. . . ~ __
3~1 C6~5 ____ 1.7
3 . 2 ~3\ C~3 1 . 22
. ___ _ . .. , ~
3.3 (~l3~ _ Cii3 1.16 ___
3 . 4 ~C:L CH3 1 . 21 ~T
.. _ ~ --C~3 1. 2~ _~
CH3
3 . 5H3('~ 3 1 .15 M p ~ 55 C
~ __ ~ . . ~ D, L
3 . 7CF3-~ C~-13 1 .19
~.____ ____ ___ ._ _ ~ _ . . __
3 . 8Cl~ C~13 1 . 2 0 M p 61 C
__ .. __ _ . . _~__~_ __._ . D, L ____
3, 9 H3C~C)~-- C~3 1 ~14 M p ' 53C
__ ~ _____ __ _ _ ._ ___._.__~ D, ~

~ 93~
_ 26 _
Tab l e 3 cont i nued
.__ ____ .
Car~ nd~R3 1 I Prepared frcm
No. I Canpound No.
. _ _ .,,. . ___
3 .10Cl-- ~ C~ 1 . 30 2
D(~) ~ ~ ~ 5 = +1 / (
3.11 CH 1.31 Mp.: 55 C
D ( + )ll C -~ 3 [cl ] D = + 2 . ~ 'C'13 )
_~_ .. ~ _~_................. __ __ _
3.12 H C~ CH3 1.32 Mp.: 5~ C
D(+) 3 ~C~]D = + 2.~', (ClICl3)
___ _~ . . ~ . .~_____
3.13 F~ CH3 1.18 Bpo 1 = 150C
. _~ . __ __ _ D, L _ ___
3.14 ~ S~3 1.33 BP'0~1 ~ 150 C
D t ~ ) _ _ ~ D + 1 . 7 ( l~iCl 3 )
_ _ ___ _ _ _ _____
3.15 ~ C~3 1.35 Bpo 6 = 165&
~~ . ~ 5 - -2.2 (C-:Cl

~L ~93~
~ 27 -
_ample 12
DL-2-(6 phenylpyridin-2-oxy)~propyl acetate
2.3 ~ of acetic anhydride are aclded dropwise at room
ternperature and while stirring to a solution oF 406 ~ of DL-
-2-(6-phenylpyr;d;n-2 oxy)-propanol (from Exarnple 9~ in 10 ml
of pyridine, stirring is continued for 4 hours a~ 6nc and
the m;xture is cooled and poured ;nto 50 ml of ;ce water~
which is extracted w;th CH2Cl2 and the extract is worked up
;n a custornary manner~ The residue is d;st;lled under a
greatly reduced pressure~ Th;s gi~es 4.3 CJ t80~/~ 0~ theory~
of a colorless oil~ boiling point 153--155C at 0~3 rnb~r.
Example 13
___._
The following compounds of the fornlula I5 listed ;n
Table f-~, are prepared ;n accorc!~nce with Exampl.e 12r but
us;ng corresponding quant;ties of compounds from Table 3 and
acet;c anhydr;de.

3~
- 28 --
Table 4
J~--C - CH - O - C - C f l 3
R3
,
CaTpo~rcl . R3 Prepared fr~
No~ Cc~npourd No~
~ . __~__ _
4.1 ~ 3.2 ~
._ , _ _
4.2 ~13 3.3
~ _.. ___
4.3 (~Cl 3.4 ___~_
4 . 4CH 3 3 . 5
H C - C -
C~3 ~ . .
_ .
4 . 5H 3 C~>- 3 . 6
_._ ___ _ ___
4 . 6F3 C-~ 3 . 7
___ _ __ ~
4.7-- Cl-~ 3.8 .
_ ____~._ __ _ ._
4 . 8 H3 C-O-(~ 3 . 9
__.__ _ _. ____~____ _~
D ( ~ ) L F~ 3 . 1 4 ~

336~'~
Example 1/~
DL-2-t6-phenylpyridii1-2-oxy)-propyl isobutyrate
A solution of 201 g of isobutyryl chloride -in 5 ml
of methylene chloride is added dropwise, while st;rring and
cooling at 0C, to a solut;on of 4.6 g of DL~2-~6-phenyl~
pyridin-2-oxy)-propanol ~frorn Example 9) in Z0 rnl of methyl.
ene chloricle and 2.2 g of tr;ethylan1;ne, ancl the m;xture is
allowecl to warm up to room temperature and stirring ;s then
cont;nued under reflux for 2 hoursu After cool;ng, tl-e rn;x~
ture is extracted by shakiny ~lith water, tl1e extract is
worked up in a customary manner and the residue is d;stilled
under a greatly reduced pressure~ This gives ~ g (67% of
theory) of product, boiling point: 155 158C at 0.2 mbar.
Example 15
The follow;ng compounds of the formul.a I, listed in
TabLe 5, are prepared in accordance with Example 14, but
using equivalent quantities of compounds frorn Examples 9
10 or Table 3 ancl a corresponding acyl chloride:
Table 5
_
,

~9360;~
_ 30 -
Tab l e 5 c.ont i nuPd
_._______ __
C~T~R2 R3 ¦f rorn
No. . Compoun~l
__ ______ , _.___ (1~.) __ ___._
5 .1 O <~>Examp le P 0 2=155-1 58C
-c~2~c- (c~2) 2-CH3 9 D,L
~ ~__ ---- _ __ _ __
5.2 O Example B,oO 5= 160-165 C
-c~2~C--tcrl- -bU~ ~ 9 D, L
. ~ _ . _ _ ___ _ _ ____
5 . 3 O . . - E xamp l e Bp 0 6=175-1 80C~C
- ---- C~2 ~C~CH2~G~3~~C~3 ~C(CH ) _ ___ D~L
5 . 4 O Exarnp le Bp .0 3=1 65-1 70 C
_CH;~_O-C--C2H5 ~ 9 D,L
5 . 5 _ _ _ E x amp i e; Bp = 17 0-1-7~ C`
-CL~2~ C~ ~ 9 . D ~ O ~ 5
_ _ . _ _ ___ _ _ _
5.6 O Example
{~2{~-C~ ~ 9
. _ . ___ _._ _ .___ . _
5. 7 O Examp le Mp : 62--64 C
_CL~2~C_C~;3 ~ 9 D, L
5 . 8 O --- ~ _~ E xamp l e Mp : 68~70C
C.~2~}C~ ~ 9 D, I,
5 . 9 O - - ~ _ _ . E x a m p l e _ ~ . . - __
Cf~2--(}C~> <~ 9 D,L
_ _ _ , _ _ _ _ ~ _.__ . _
5 . 10 O E xamp l e Mp ~ 6~3-69 C
2~ C- ~3 ~Cl ~ 9 D, L
~ _ ~._ _~ _.__ _ _
5. 1 1 _ Example
-C~2~C--~ 3 C~
_~_ ~ ~ _.. ... _ ~_ ____ .
.

1~936~
_ 31 -
Tab l e 5 c_nt i n ued
C0,7~a ncl R2 R3 Prepared
Nb~ f roin
Co~ound
~ _ __ __ , , _ _ _~10 ) _ .. __ _ _.__
5.12 0 Example
-C~2~C4~ 0~-I3 (~ 9
. _ .. .. _ _ _, _............... ._ _.
5 . 13 -C~ -0 C- ~ CF ~ E x amp l e
. _ ... . ------ ' ' ___ _____ _
5.1'1 O C~l Example
-CH2-0-C ~> ~ 9
. _ . . ~ _ _ .. _ ~
5. 15 ., _ Example Bp 0 3=153-155 C
D~+) CE~2~C-CH3 ~ 10[~)25 = ~3,4
((:E-IC13)
_ _ . _ _ .. __. . .......... ____
S.16 0 Example Bp 165-168C
D(+) -C~H2{~C-C2H5 ~ 10 0~25 0
_ _~ ~ (C~,C13)
5 . 17 = ~ _~ E x a mp l e o 2= 155-1 5bC
D(~-) -~I2-~C-C3~7 ~ 10 [C~J~5 = +3.2
(G'IC13 )
. _ . _ . . __ _ ______
5.18 O Example E3p 0 2=155-158 C
D(+) -c~I2~~c-G~(G'I ) ~ 10 [Q]25 = + 3 3
_ __ _ _ ~ _ _ - _ 3 ___
5.19 0 3.1
D ( +; CH2C) -C-C'H ~ _
_ __ _ . __~ _ _____ ~
5.20 0 3.14
V ( ~ ) "
5.21 _ ~___ ~___
D (+) -C~2~C-C~ (C7~3 ) 2 - F'-~>- 3 .14
. ~ __ __. ~ ~

~93~
~ 32-
Tab l e S cont i nued
Prepared
Ccrrpound R2 R3 f rom
No. Ccmpo~md
5 . 22 . ~___ _ __ _ ___(No. )
D (+) -CH2~C-C3~i7 ~) 3 . 14
. __ ___... __ __ ~_
5 . 23 O M p: 75-76C
D(l) " 0~ Cl~- 3.10 [~)D = + 6.0
. ~_~ . __ ~ (~ICl3 )
5. 2~ O Bp = 173-17~1 C
D (+) ~, Cl-~ 3 .10 ~5
. C~ICl3)
_ ____ . . .. ____

36V,'~
- 33 -
Exann~le 16
DL~2-(6-phenylpyr;din 2-oxy) propyl methyl ether
A solution of ~.6 9 of DL-2-(6-phenylpyrid;n-2-
oxy)-propanol (from Example ~) in 5 ml of absolute telra-
hydrofuran (THF) is added dropwise, while stirr;ng at 20C~to a suspension oF 0.6 9 of YaH (~0% strength dispersion
in oil~ în 30 ml of absolute THF, stirr;ng is continued until
the evolut;on of hydrogen is complete, the mixture is cooled
to ûC, a solution of 2.8 g of methyl iodide is added drop-
wise, and the mixture is allol~ed to ~Jarrn up to room tempera~ture and is then boiled under reflux for 2 hours. After
cooling, the solvent is removed under reduced pressure, work-
ing up ;s carried out in a customary manner with water/methyl-
ene chlor;de ~nd the residue is d;stilled under a ~reatly
reducec! pressure. This gives 3.9 9 (8bx of theory) of pro-
duct, boil;n~ po;nt 128-131C at 0.5 mbar.
Example 17
~L-2~(6-phe _lpyrid;n-2 oxy)-propyl butyl ether
4.3 9 t75% of theory) of this product are obtained
;n accordance with Example 16, bu~ us;ng 4.~ 9 of DL-2-t6-
phenylpyr;clirl-?-oxy)~propanol ~from Exanlple 5) and ?..7 g
of n butyl bromidei
Example 1 8
3L~2-(6~phenylpyridin 2~oxy~-propanal
?5 The exper;lment is carr;ed out under nitrogen as an
;nert gas. A solut;on of ~.78 ml of dirnethyl sulfox;de in
10 ml of ai~solute methylene chlor1de ;s added dropwise, wllile
stirr;ng at -hOCo to a solution of 2.32 ml of oxaLyl chloride
;n 25 ml of absolute methylene chlor;der stirring is contirl-led

36~
~ 34 -
for a further 5 m;nutes and a solu~;on of 3.7 g of DL-2-(6
phenylpyridin-2-oxy~ propanol (from Example 9) in 20 ml of
absolute methylene chloride ;s then added all at oncen Stir
ring is then continued at -60C for Z0 minutes, 1~4 ~l of
triethylamine are added, the mixture is allowed to ~Jarm up
slo~lly to room teMperature and 50 rnl of water are then added
and the product is worked up in a customary manner. The
residue is taken up in 40 rnl of ether, the sol~ltion is fil-
tered through Celite and the solvent is removed under reclllced
pressure. This gives ~ g (S6'~ of theory~ of a colorless
oi l.
Examples of the preparation of compounds of the fornlula XI
Example 19
6-Phenylpyrid~2-one
__
1~ a) Methyl 5-phenyl-5-oY~opentanoate
3,220 g of acetophenone, 484 g of rnethyl acrylate,
80 g of isopropylamine and 2.7 g of benzoic acid are h~ated
at 200C for 3 hours in a 5 liter autoclave. In addition to
unreacted methyl acrylate and acetophenone, the subsequent
distillation under reduced pressure gave 640 g of product,
boiling point 175C at 7~5 mbar (55~5% of theory relative
to methyl acrylate).
b) 6-Phenyl-3,4 dihydropylid-2-one
300 g of methyl 5 phenyl-5-oxopentanoate are heated
to 180C in a 500 ml flask equipped with a descending con~
denser. Ammonia is then passed in for 3 hours. In the
course oF this the \~ater and methanol formed d1stil c,Ff through
the descending condenser~ After cooling~ the reactiol1 m1xture
solidifies to give a mash of crystals. The mixt-lre is fil~ered

~93~13'h
- 35 -
with suction and 130 g (53% of theory3 of product, melt;ng
point 158C, are obtained. The mother liquor contains
mainly unreacted starting material.
c) 6 Phenylpyrid-2-one
250 ml of methylbutyld;glycol and 5 9 of catalyst
(2% strength Pd-on~charcoal) were added to 30 g o-f 6-phenyl-
3,4~d;hydropyrid~2-one in a 500 ml glass flask equ;pped with
a stirrer, a thermometer, a descending condenser and a gas
meter. The apparatus ~las flushed w1th nitrogen and the
methylbutyldiglycol was then heated to reflux temperature
In the course of ~h;s ~.3 liters of exit gasr composed of
90% oF hydrogen, were formed dur;ng 5 hours. The apparatus
was aga;n flushed ~;th N2; ~he solution was freed from
the caLal,st by filtration ~!hi!e hot~ ~n coolln~; 25r3 9
(82X of theory) of product, melting poin'c 198C, crystallized
out from the mother liquor.
The catalyst can be used againO Even a-Fter being
employed ten times, the yield of 6-phenylpyrid~2~one is
approxilnately 80%~
Z0 Example Z0
-
The following compounds of 'he forlnula II, listed
in Table 6, are prepared in accordance with Example 1~, but
using corresponding quantit;es of a kecone of the -formula
O
R3-C-CH-~ and of an acryl;c acid ester of the formula
Cll .
Cl12=Cr~~C~O~C~l~5:

i~93Ei~
36 _
Table 6
___
Il L
N~O
H
Con~nd R
No. 3 . Melt ing poi n-t; ~ (3
~ .__ ___.__
6. ~ M3C;~_
, _______, _ . _ ______
6 . 2 C~13O~ 172-176 a~
6 . 3 _ . .. . . _ 1 7 0 - 1 7 5 a )
~'3C-~
__ _ __. _ _
6.4 ~CT~3
. . C 1 _ _._ ._
6.S Cl~
~ _ _ ___ ~
6.6 F~- . 178-183 a~
. ~ _ ~ ~
6 .7
F3C4
____ ~_____ __ ~
6 . 8 . 2G3-204
_ Cl~-
_~ __ . _ .~_ _ _ _
.
a) Melting point not sharp because of slight impllrities in
the cc>rresponding 3,l~,.5,6-tetrahydropyridin-2-ones.
. ,
,

37 _
Table 6 contin~led
_ _
C onpamd; R3 ....
No. . Melting point: Lc]
_ _. ~ .~
6.9 ~-Cl
6. 10 CH3
CH3
6.11 ¦
__

Representative Drawing

Sorry, the representative drawing for patent document number 1193602 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Inactive: Expired (old Act Patent) latest possible expiry date 2003-03-25
Inactive: Reversal of expired status 2002-09-18
Inactive: Expired (old Act Patent) latest possible expiry date 2002-09-17
Grant by Issuance 1985-09-17

Abandonment History

There is no abandonment history.

Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
HOECHST AKTIENGESELLSCHAFT
Past Owners on Record
ERNST BLUME
RUDOLF SCHLEYERBACH
WERNER H. MULLER
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Cover Page 1993-06-17 1 20
Abstract 1993-06-17 1 9
Claims 1993-06-17 5 69
Drawings 1993-06-17 1 7
Descriptions 1993-06-17 36 859